Results 331 to 340 of about 2,154,176 (393)
Some of the next articles are maybe not open access.
Novel mitogen-activated protein kinase kinase inhibitors
Expert Opinion on Investigational Drugs, 2011the development of new drugs over the last few decades has targeted specific proteins thought to be a key to the disease state. MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF.
Mark S, Chapman, Jeffrey N, Miner
openaire +2 more sources
Inhibitors of protein tyrosine kinases
Current Opinion in Biotechnology, 1995The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire +2 more sources
Peptide Inhibitors Targeting Protein Kinases
Current Pharmaceutical Design, 2009Phosphorylation by protein kinases is a central theme in biological systems. Aberrant protein kinase activity has been implicated in a variety of human diseases, therefore, modulation of kinase activity represents an attractive therapeutic approach for the treatment of human illnesses.
Hagit, Eldar-Finkelman +1 more
openaire +2 more sources
Non-ATP Competitive Protein Kinase Inhibitors
Current Medicinal Chemistry, 2010Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors are ATP-competitive and are called type I inhibitors. The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents.
GARUTI, LAURA +2 more
openaire +4 more sources
Emerging protein kinase inhibitors for non-small cell lung cancer
Expert Opinion on Emerging Drugs, 2013Introduction: In the current paradigm of precision medicine in non-small cell lung cancer (NSCLC), the therapeutic strategy is determined by the molecular characteristics.
Stephen V. Liu +4 more
semanticscholar +1 more source
Bacterial protein kinase inhibitors
Drug Development Research, 2010AbstractProtein kinases have become the second most important group of drug targets for the pharmaceutical industry next to G‐protein‐coupled receptors. Thus, over the past decade, a significant number of small molecules have been generated for protein kinase drug optimization programs. The vast majority of kinase inhibitors target the ATP binding site
Michio Kurosu, Eeshwaraiah Begari
openaire +1 more source
Rottlerin, a Novel Protein Kinase Inhibitor
Biochemical and Biophysical Research Communications, 1994Rottlerin, a compound from Mallotus philippinensis, is shown to inhibit protein kinases with some specificity for PKC. To some extent, the novel inhibitor is able to differentiate between PKC isoenzymes, with IC50 values for PKC delta of 3-6 microM, PKC alpha,beta,gamma of 30-42 microM and PKC epsilon,eta,zeta of 80-100 microM.
M, Gschwendt +6 more
openaire +2 more sources
Properties of FDA-approved small molecule protein kinase inhibitors.
Pharmacological Research, 2019R. Roskoski
semanticscholar +1 more source
Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update.
Pharmacological Research, 2019R. Roskoski
semanticscholar +1 more source
The contemporary management of cancers of the sinonasal tract in adults
Ca-A Cancer Journal for Clinicians, 2023Rajat Thawani
exaly